Alendronic acid
- Generic Name
- Alendronic acid
- Brand Names
- Adrovance, Binosto, Fosamax, Fosamax Plus D, Fosavance
- Drug Type
- Small Molecule
- Chemical Formula
- C4H13NO7P2
- CAS Number
- 66376-36-1
- Unique Ingredient Identifier
- X1J18R4W8P
- Background
Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease. It functions by preventing resorption of bone.
- Indication
Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of bone. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance <35mL/min.
- Associated Conditions
- Osteogenesis Imperfecta (OI), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget’s Disease
- Associated Therapies
- -
Glucocorticoids Promote Osteoclast Survival
- First Posted Date
- 2007-12-13
- Last Posted Date
- 2011-08-30
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 3
- Registration Number
- NCT00572299
- Locations
- 🇺🇸
University of Arkansas hospitals and clinics and the Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States
Denosumab Adherence Preference Satisfaction Study
- First Posted Date
- 2007-08-20
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- Amgen
- Target Recruit Count
- 250
- Registration Number
- NCT00518531
A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
- Conditions
- Interventions
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2011-06-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 801
- Registration Number
- NCT00503113
A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)
- Conditions
- First Posted Date
- 2007-05-31
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 60
- Registration Number
- NCT00480662
A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.
- Conditions
- Interventions
- First Posted Date
- 2007-05-09
- Last Posted Date
- 2017-11-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 564
- Registration Number
- NCT00471237
- Locations
- 🇪🇸
GSK Investigational Site, Santiago de Compostela, Spain
Osteoporosis Prevention With Low Dose Alendronate
- Conditions
- Interventions
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2013-05-29
- Lead Sponsor
- University Hospital of Mont-Godinne
- Target Recruit Count
- 83
- Registration Number
- NCT00463268
- Locations
- 🇧🇪
University (UCL) Louvain Hospital in Mont-Godinne, Yvoir, Namur, Belgium
The Change of Bone Markers After Low Dose Alendronate in Postmenopausal Women With Bone Loss
- First Posted Date
- 2007-04-13
- Last Posted Date
- 2014-08-05
- Lead Sponsor
- Eulji University Hospital
- Target Recruit Count
- 63
- Registration Number
- NCT00460057
Study of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2006-11-02
- Last Posted Date
- 2010-02-09
- Lead Sponsor
- Monash University
- Target Recruit Count
- 50
- Registration Number
- NCT00395382
- Locations
- 🇦🇺
Department of Nephrology, Monash Medical Centre, Clayton, Victoria, Australia
Fosamax for Childhood Cancer Survivors
- First Posted Date
- 2006-10-24
- Last Posted Date
- 2008-05-23
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 100
- Registration Number
- NCT00391404
- Locations
- 🇭🇰
Prince of Wales Hospital, Shatin, N.T., Hong Kong, Hong Kong
Study of Transitioning From Alendronate to Denosumab
- Conditions
- Interventions
- First Posted Date
- 2006-09-18
- Last Posted Date
- 2011-07-11
- Lead Sponsor
- Amgen
- Target Recruit Count
- 504
- Registration Number
- NCT00377819
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.